Joaquim Raduà

A phase 2 clinical trial has tested the efficacy and safety of a transcranial magnetic stimulation device used at home to treat major depression in 174 patients. After dividing them into two groups, one group received the treatment and the other a placebo procedure. After ten weeks, both groups had improved their symptoms, but the improvement in the active treatment group was 0.4 points greater on the Hamilton depression scale. According to the authors, who publish the results in the journal Nature Medicine, ‘it could potentially serve as a first-line treatment for major depression’.

A Finnish study involving more than 700,000 adolescents has found some risk of transmission of some mental disorders among classmates. The results are published in the journal JAMA Psychiatry. 

The largest meta-analysis to date that studies the risk of children of people with a mental disorder also suffering from some type of mental disorder during their lifetime has been published, with Spanish participation. According to the study, the risk is more than double that of the rest of the population. To explain the study and resolve any doubts that may arise, the Science Media Centre Spain organised an information session with one of the authors, psychiatrist Joaquim Raduà.

Apps developed to treat depression may be beneficial in the management of severe and moderate cases. This is the conclusion of a review and meta-analysis that included 13 studies with up to 16 different apps. The results are published in the journal JAMA Network Open.

A phase 1 clinical trial has tested the use of psilocybin to treat anorexia nervosa. Ten women with the disorder were given 25 milligrams of the hallucinogen along with psychological support. The results show that the treatment is safe and tolerable. Four patients showed an improvement, but the authors acknowledge that, because of the small sample size and the absence of a control group, "the results are preliminary and further research is needed". The results are published in the journal Nature Medicine.

Beta-blockers (β-blockers) are drugs to treat heart conditions that are also used for anxiety. According to research published in PLOS Medicine, periods of treatment with these drugs are associated with a lower risk of being charged by the police with a violent crime - a 13% lower risk than periods without treatment. The research, which included nearly 1.5 million people in Sweden between 2006 and 2013, does not support the use of these drugs to treat anxiety.

Research among more than 7,000 US adults shows small changes in extraversion, agreeableness, openness to change and conscientiousness between the period before the covid-19 pandemic and the year 2022, especially in younger people. The study is published in PLOS ONE.